Karbis (Candesartan Cilexetil)

Karbis (candesartan cilexetil) is employed to treat conditions involving the renin‑angiotensin system and cardiovascular disease.

• Hypertension: lowers systolic and diastolic blood pressure, helping to reduce the risk of stroke, myocardial infarction, and other cardiovascular events.
• Heart failure: decreases ventricular afterload, improves cardiac output and symptoms such as dyspnea, leading to better functional capacity and fewer hospitalizations.
• Diabetic nephropathy: slows progression of kidney damage by reducing intraglomerular pressure and proteinuria, thereby preserving renal function in patients with diabetes.

• Candesartan cilexetil is a prodrug that is rapidly hydrolyzed to candesartan, a selective antagonist of the angiotensin II type 1 (AT1) receptor. By blocking AT1 receptors, it prevents angiotensin II‑mediated vasoconstriction, aldosterone secretion, and sympathetic activation, resulting in vasodilation, reduced sodium and water retention, and lowered blood pressure, which together improve cardiac workload and support long‑term cardiovascular protection.

Candesartan cilexetil may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate head pain.
• Fatigue: feeling unusually tired or weak.
• Hyperkalemia: elevated blood potassium levels detected in laboratory tests.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue or throat that may compromise airway.
• Severe hypotension: marked drop in blood pressure causing fainting or shock.
• Acute renal failure: sudden decline in kidney function, indicated by rising creatinine.
• Hepatic injury: abnormal liver enzymes or jaundice.

When prescribing candesartan cilexetil, clinicians should observe several precautionary measures to ensure patient safety.

• Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension.
• Renal function assessment: evaluate serum creatinine and eGFR before initiation and during therapy.
• Electrolyte surveillance: monitor serum potassium, especially in patients on potassium‑sparing agents.
• Use in hepatic impairment: adjust therapy cautiously in moderate to severe liver disease.
• Pregnancy and lactation: avoid use unless benefits outweigh risks, as safety data are limited.
• Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Candesartan cilexetil can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Concomitant use with aliskiren in patients with diabetes: may increase risk of renal impairment, hyperkalemia, and hypotension.
• Dual blockade with ACE inhibitors or other ARBs: can cause additive hypotensive effects and kidney dysfunction.

Moderate Interactions (Monitor Closely)

• Potassium‑sparing diuretics (e.g., spironolactone, amiloride): may raise serum potassium levels.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): can reduce antihypertensive effect and impair renal function.
• Lithium: candesartan may increase lithium concentrations, risking toxicity.